Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | F2 | P00734 | 7/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6846378 | 0.83 | KDM4E (0.44) | KDM4EALDH1A1F2TSHRHPGD | |
| SCHEMBL6850301 | 0.81 | KDM4E (0.41) | KDM4EALDH1A1F2HPGD | |
| SCHEMBL6850252 | 0.76 | F2 (0.56) | KDM4EALDH1A1MEN1KMT2AF2 | |
| SCHEMBL7736669 | 0.76 | TNF (0.46) | ALDH1A1TNF | |
| SCHEMBL7737504 | 0.76 | F2 (0.44) | KDM4EALDH1A1F2 | |
| SCHEMBL6849324 | 0.73 | MASP2 (0.38) | KDM4EALDH1A1F2HPGD | |
| SCHEMBL6848920 | 0.70 | TNF (0.50) | KDM4EALDH1A1MAPTTNF | |
| SCHEMBL6848928 | 0.69 | TNF (0.49) | KDM4EALDH1A1TNF | |
| SCHEMBL6850663 | 0.68 | F2 (0.64) | F2 | |
| SCHEMBL23460608 | 0.68 | F2 (0.54) | KDM4EALDH1A1MEN1KMT2AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777431-B2 | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2004-08-17 | — | — | US | disclosed |
| US-6777431-B2 | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2004-08-17 | — | — | US | disclosed |
| US-6777431-B2 | ANTICOAGULANTS | CORVAS INTERNATIONAL, INC. | 2004-08-17 | — | — | US | disclosed |
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | DENDREON PHARMACEUTICALS LLC | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092679-A1 | Novel non-convalent thrombin inhibitors | F2, SERPINC1, F2RL3 | KDM4E 3434/4885ALDH1A1 4674/4885MEN1 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.